半乳糖凝集素3(GAL3)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Galectin 3 (GAL3)
LGALS3; CBP35; GALBP; GALIG; MAC2; 35 kDa lectin; Carbohydrate-binding protein 35; Galactose-specific lectin 3; Galactoside-binding protein; Laminin-binding protein; Lectin L-29
- 編號(hào)USEA303Ra
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱(chēng)，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍0.156-10ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.057ng/mL.
- 樣本類(lèi)型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 1436 ¥ 2052 ¥ 9234 ¥ 17442 ¥ 143640
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線(xiàn)圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)半乳糖凝集素3(GAL3)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的半乳糖凝集素3(GAL3)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 78-96 | 81 |
| EDTA plasma(n=5) | 78-97 | 88 |
| heparin plasma(n=5) | 99-105 | 102 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線(xiàn)性
在定值血清及血漿樣本內(nèi)加入適量的半乳糖凝集素3(GAL3)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線(xiàn)性范圍即為稀釋后樣本中半乳糖凝集素3(GAL3)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 88-95% | 90-97% | 81-101% | 79-97% |
| EDTA plasma(n=5) | 98-105% | 91-98% | 84-91% | 90-98% |
| heparin plasma(n=5) | 78-98% | 92-102% | 86-98% | 78-91% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將半乳糖凝集素3(GAL3)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的半乳糖凝集素3(GAL3)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的半乳糖凝集素3(GAL3)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的半乳糖凝集素3(GAL3)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UAPA303Ra01 | 半乳糖凝集素3(GAL3)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPA303Ra01 | 半乳糖凝集素3(GAL3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA303Ra01 | 半乳糖凝集素3(GAL3)多克隆抗體 | WB; IHC |
| UFAA303Ra01 | 抗半乳糖凝集素3(GAL3)多克隆抗體 | FCM |
| ULAA303Ra81 | 半乳糖凝集素3(GAL3)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| ULAA303Ra71 | 半乳糖凝集素3(GAL3)多克隆抗體(生物素標(biāo)記) | IHC |
| UMAA303Ra24 | 半乳糖凝集素3(GAL3)單克隆抗體 | WB |
| UMAA303Ra23 | 半乳糖凝集素3(GAL3)單克隆抗體 | WB |
| UMAA303Ra21 | 半乳糖凝集素3(GAL3)單克隆抗體 | WB; IHC |
| UMAA303Ra22 | 半乳糖凝集素3(GAL3)單克隆抗體 | WB; IHC |
| UFAA303Ra04 | 抗半乳糖凝集素3(GAL3)單克隆抗體 | FCM |
| UFAA303Ra06 | 抗半乳糖凝集素3(GAL3)單克隆抗體 | FCM |
| UFAA303Ra02 | 抗半乳糖凝集素3(GAL3)單克隆抗體 | FCM |
| USEA303Ra | 半乳糖凝集素3(GAL3)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA303Ra | 半乳糖凝集素3(GAL3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Clinica Chimica Acta | Galectin-1 and galectin-3: plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population [Pubmed:25578395] |
| Scientific Reports | Biomarkers and Echocardiographic Predictors of Myocardial Dysfunction in Patients with Hypertension [PubMed: 25747153] |
| Int J Mol Sci | The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension [PubMed: 25984599] |
| Scientifi Reportcs | Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices [PubMed: 26582585] |
| Clin Chim Acta | Galectin-1 and galectin-4: Plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population [PubMed: 25578396] |
| JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION | Galectin-3 mediates the pulmonary arterial hypertension-induced right ventricular remodeling through interacting with NADPH oxidase 4. [pubmed:28431936] |
| 昆明醫(yī)科大學(xué)學(xué)報(bào) | 半乳糖凝集素3 在COPD 和肺癌中的表達(dá)及其意義. [2095610X] |
| Archives of Medical Science | Can we define migraine patients with blood high-sensitivity C-reactive protein and galectin-3 levels in the emergency department? [publication:305625095] |
| Biosensors & Bioelectronics | A sensitive sandwich-type immunosensor for the detection of galectin-3 based on N-GNRs-Fe-MOFs@AuNPs nanocomposites and a novel AuPt-methylene blue nanorod. [pubmed:29096363] |
| Scientific Reports | The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction. [pubmed:28827564] |
| Clinica Chimica Acta | Galectin-3 in patients with coronary heart disease and atrial fibrillation [Pubmed:29287900] |
| Advances in Experimental?Medicine?and?Biology | Molecules of Damage-Associated Patterns in Bronchoalveolar Lavage Fluid and Serum in Chronic Obstructive Pulmonary Disease [Pubmed:29429028] |
| FASEB?Journal | Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure [Pubmed: 30230922] |
| american journal of physiology-heart and circulatory physiology | Macrophage galectin-3 enhances intimal translocation of vascular calcification in diabetes mellitus [Pubmed: 32216615] |
| Cardiology | Galectin-3 Induces Atrial Fibrosis by Activating the TGF-β1/Smad Pathway in Patients with Atrial Fibrillation [Pubmed: 32516780] |
| AUSTRALIAN DENTAL JOURNAL | The effect of initial periodontal treatment on gingival crevicular fluid galectin?\3 levels in participants with periodontal disease [33378559] |
| Cell Death & Disease | Trajectory modeling of endothelial-to-mesenchymal transition reveals galectin-3 as a mediator in pulmonary fibrosis [33771973] |
| Int J Clin Pract | Serum Galectin?\3 Levels in Patients with Psoriasis [34137138] |
| Phytomedicine | Zerumbone, a humulane sesquiterpene from Syringa pinnatifolia, attenuates cardiac fibrosis by inhibiting of the TGF-β1/Smad signaling pathway after myocardial?… [Pubmed:35405613] |
| Medicine | Regulatory T cells, damage-associated molecular patterns, and myeloid-derived suppressor cells in bronchoalveolar lavage fluid interlinked with chronic obstructive?… [Pubmed:35687771] |
